Memo Therapeutics: Funding, Investors & Team (Sep 2026)
Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery. MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
Memo Therapeutics has raised $36.2M across 2 funding rounds on record, the most recent a Series B of $24.9M announced in Feb 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Memo Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2022.
Memo Therapeutics Funding Rounds
Memo Therapeutics raised $11.3M in a Grant announced in Dec 2021.
2 months later, a Series B of $24.9M was announced in Feb 2022.
Memo Therapeutics Founders and Leadership Team
Contact details for the Memo Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Memo Therapeutics Funding Compared to Other Biotechnology Startups
Memo Therapeutics' latest round of $24.9M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Memo Therapeutics in Biotechnology and Schlieren
Companies Similar to Memo Therapeutics
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
Memo Therapeutics Funding FAQs
What does Memo Therapeutics do?
Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery. MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
How much funding has Memo Therapeutics raised?
Memo Therapeutics has raised $36.2M across 2 rounds on record. The most recent is a Series B of $24.9M announced in Feb 2022.
When did Memo Therapeutics last raise funding?
Memo Therapeutics' most recent funding round on record is a Series B of $24.9M, announced in Feb 2022.
Who is the CEO of Memo Therapeutics?
Karsten Fischer is listed as CEO at Memo Therapeutics.
Where is Memo Therapeutics headquartered?
Memo Therapeutics is based in Schlieren, Zurich, Switzerland.
How many employees does Memo Therapeutics have?
Memo Therapeutics is in the 11-50 employee band.
How does Memo Therapeutics' funding compare to other Biotechnology startups?
Memo Therapeutics' latest round of $24.9M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Memo Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Memo Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.